Magnetic Resonance Imaging for Prediction and Assessment of Treatment Response in Bevacizumab-Treated Recurrent Glioblastoma
Glioblastoma is the most common primary brain tumor in adults, and it is associated with a dismal prognosis with a median survival of 15 months. Despite treatment with chemotherapy, radiation therapy and surgery, patients inevitably have disease recurrence. Bevacizumab is a monoclonal humanized anti...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | en |
| Published: |
Harvard University
2014
|
| Subjects: | |
| Online Access: | http://etds.lib.harvard.edu/hms/admin/view/65 http://nrs.harvard.edu/urn-3:HUL.InstRepos:12407623 |